Short Interest in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Drops By 5.9%

Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Free Report) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 19,600,000 shares, a decrease of 5.9% from the November 30th total of 20,830,000 shares. Based on an average daily volume of 2,550,000 shares, the short-interest ratio is presently 7.7 days.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 22,901 shares of company stock worth $259,863 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the company. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. increased its position in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. raised its stake in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in shares of Amicus Therapeutics during the third quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics in the third quarter worth $55,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on FOLD shares. Cantor Fitzgerald increased their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Guggenheim raised their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

View Our Latest Stock Analysis on FOLD

Amicus Therapeutics Trading Up 0.1 %

NASDAQ FOLD opened at $9.42 on Thursday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -27.71 and a beta of 0.60. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.53. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The business’s fifty day moving average is $10.21 and its 200 day moving average is $10.57.

Amicus Therapeutics Company Profile

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

See Also

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.